IPS cells from Chediak‐Higashi syndrome patients recapitulate the giant granules in myeloid cells. Issue 1 (12th December 2022)

• Record Type: Journal Article
• Authors: Oh, Shigeharu; Niwa, Akira; Nagahashi, Ayako; Asaka, Isao; Nakahata, Tatsutoshi; Saito, Megumu K.
• Is Part Of: Pediatrics international. Volume 64:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-12
• Subjects: Chediak‐Higashi syndrome -- induced pluripotent stem cells -- myeloid cells; Pediatrics -- Periodicals; 618.92
• DOI: 10.1111/ped.15390
• Languages: English
• ISSNs: 1328-8067

Abstract

Abstract: Background: Chediak‐Higashi syndrome (CHS) is a congenital disease characterized by immunodeficiency, hemophagocytic lymphohistiocytosis, oculocutaneous albinism, and neurological symptoms. The presence of giant granules in peripheral blood leukocytes is an important hallmark of CHS. Here we prepared induced pluripotent stem cells (iPSCs) from CHS patients (CHS‐iPSCs) and differentiated them into hematopoietic cells to model the disease phenotypes. Methods: Fibroblasts were obtained from two CHS patients and then reprogrammed into iPSCs. The iPSCs were differentiated into myeloid cells; the size of the cytosolic granules was quantified by May‐Grunwald Giemsa staining and myeloperoxidase staining. Results: Two clones of iPSCs were established from each patient. The differentiation efficiency to CD33 + CD45 + myeloid cells was not significantly different in CHS‐iPSCs compared with control iPSCs, but significantly larger granules were observed. Conclusions: We succeeded in reproducing a characteristic cellular phenotype, giant granules in myeloid cells, using CHS‐iPSCs, demonstrating that iPSCs can be used to model the pathogenesis of CHS patients.